Sign in
4

Changes in Ownership

Atea Pharmaceuticals, Inc. Filed Acc 0000899243-22-004181

Options or other derivatives

  • Chief Development Officer acquired 190,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Hammond Janet MJ Chief Development Officer 2022-01-31 Grant or award · Stock Option (Right to Buy) +190,000 190,000 D
Loading xslF345X03/doc4.xml…